Owkin Unveils AI-Driven Oncology And Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395
Owkin, a pioneering TechBio unicorn, recently revealed its groundbreaking drug pipeline in oncology and immunology through an exclusive global licensing agreement with Idorsia. This agreement focuses on OKN4395, a cutting-edge dual inhibitor of prostanoid receptors EP2 and EP4, showcasing Owkin's commitment to precision drug discovery and diagnostics. The pipeline is a culmination of Owkin's advanced AI engines, fueled by extensive patient data from top research centers and a team of 110 data scientists. Leveraging spatial multiomics data via MOSAIC, the world's largest spatial multiomics dataset, Owkin aims to revolutionize precision medicine, addressing critical challenges with its deep expertise in immune response and AI-driven drug discovery projects.
Owkin's AI engines meticulously selected OKN4395 for in-licensing, employing multimodal patient data to identify actionable biomarkers and screen over 30 cancer indications. The integration of rich patient data allowed Owkin to decipher the intricate biology of EP2/EP4, revealing its significant impact on T cell connectivity within the tumor microenvironment. By applying AI to de-risk clinical trials and optimize treatment strategies, Owkin is poised to accelerate precision medicine, advancing towards tailored treatments for individual patient subgroups. Through strategic partnerships and cutting-edge technologies, Owkin continues to expand its pipeline, promising innovative solutions in oncology, immunology, and inflammation, while Idorsia's expertise in drug discovery further strengthens this collaborative endeavor.
Comments
Post a Comment